Press release
DelveInsight's "Behcet's Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Behcet's Disease, historical and forecasted epidemiology as well as the Behcet's Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Behcet's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Behcet's Disease Market Forecast
https://www.delveinsight.com/sample-request/behcets-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Behcet's Disease Market Report:
• The Behcet's Disease market size was value ~USD 140 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In August 2025, The US Food and Drug Administration (FDA) has granted orphan drug designation to dusquetide, the active ingredient in Soligenix's investigational therapy SGX945, for the treatment of Behçet's disease. The designation comes after promising Phase 2a pilot study results that showed both biological efficacy and safety in patients affected by this rare and challenging autoimmune condition.
• In July 2025, Soligenix, Inc. (NASDAQ: SNGX) reported positive findings from its Phase 2a clinical study of SGX945 in Behçet's disease (BD), where the drug showed clear biological activity. Based on these results, the company intends to move forward with a placebo-controlled Phase 2b trial. Before doing so, SGX945 will undergo reformulation, as it is currently delivered via intravenous administration.
• In March 2025, Christopher J. Schaber, PhD, President and CEO of Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with significant unmet needs, stated that the company remains committed to advancing its diverse clinical pipeline. Key upcoming milestones include the anticipated top-line results in 2026 from the ongoing confirmatory Phase 3 placebo-controlled trial evaluating HyBryteTM (synthetic hypericin) for early-stage cutaneous T-cell lymphoma (CTCL). Additionally, in the latter half of this year, Soligenix expects to announce top-line data from its ongoing Phase 2 trials of SGX945 (dusquetide) for Behçet's disease and SGX302 (synthetic hypericin) for mild-to-moderate psoriasis.
• In November 2024, Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with unmet medical needs, announced the initiation of patient enrollment for its Phase 2 clinical trial (protocol number DUS-AUBD-01) assessing SGX945 (dusquetide) as a treatment for Behçet's Disease.
• According to DelveInsight's analysis, the total number of diagnosed prevalent cases of Behcet's syndrome in the 7MM was estimated to be around 73,000 in 2023. This number is expected to grow over the forecast period (2024-2034), largely driven by greater awareness among healthcare professionals and the general public, leading to improved recognition and diagnosis of the condition.
• Among the EU4 and the UK, Italy accounts for the largest market size for Behçet's syndrome, estimated at around USD 10 billion, followed by France and Spain with approximately USD 9 billion and USD 8 billion, respectively. These figures are expected to evolve over the forecast period (2024-2034), driven by continuous research and development efforts that could lead to the introduction of more effective treatments and therapies for Behçet's syndrome.
• In 2023, the United States reported an estimated 20,000 diagnosed prevalent cases of Behcet's syndrome. Of these, about 83% were young adults, and roughly 17% were pediatric cases. The number of cases is projected to rise by 2034, potentially influenced by more sedentary lifestyles and increased exposure to infectious agents or other factors that may contribute to the development of Behcet's syndrome in the country.
• In 2023, among the EU4 and the UK, Italy recorded the highest number of diagnosed prevalent cases of Behcet's syndrome, with around 7,000 cases, followed by Spain with approximately 6,000 cases and France with nearly 5,000. According to DelveInsight's projections, these figures are expected to shift over the forecast period (2024-2034).
• In 2023, Japan reported the highest number of diagnosed prevalent cases of Behcet's syndrome, totaling nearly 33,000. Among these, around 5,000 were oral ulcer cases, 4,000 involved genital ulcers, 3,000 were related to skin symptoms, and another 3,000 were cases of arthritis. This number is projected to rise by 2034, influenced by factors such as increased migration and urbanization, which may impact disease prevalence in the country.
• Key Behcet's Disease Companies: Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others
• Key Behcet's Disease Therapies: SGX945, RAY121, Dusquetide, Filgotinib, Hemay005, Apremilast, and others
• The Behcet's Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Behcet's Disease pipeline products will significantly revolutionize the Behcet's Disease market dynamics.
Behcet's Disease Overview
Behcet's Disease is a rare, chronic, and multisystem inflammatory disorder characterized by recurring episodes of inflammation affecting various parts of the body. It is named after the Turkish dermatologist Hulusi Behçet, who first described the condition in 1937. The disease primarily affects blood vessels, causing symptoms that can involve the mouth, eyes, skin, joints, and other organs.
Get a Free sample for the Behcet's Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/behcets-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Behcet's Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Behcet's Disease Epidemiology Segmentation:
The Behcet's Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Diagnosed Prevalent Cases of Behcet's Syndrome in the 7MM
• Diagnosed Cases of Behcet's Syndrome Based on the Age of Onset in the 7MM
• Clinical Manifestations Associated With Behcet's Syndrome in the 7MM
• Total Patients Seeking Treatment for Behcet's Syndrome in the 7MM
Download the report to understand which factors are driving Behcet's Disease epidemiology trends @ Behcet's Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/behcets-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Behcet's Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Behcet's Disease market or expected to get launched during the study period. The analysis covers Behcet's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Behcet's Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Behcet's Disease Therapies and Key Companies
• SGX945: Soligenix
• RAY121: Chugai Pharmaceutical
• Dusquetide: Soligenix
• Filgotinib: UMC Utrecht
• Hemay005: Ganzhou Hemay Pharmaceutical
• Apremilast: Amgen
Discover more about therapies set to grab major Behcet's Disease market share @ Behcet's Disease Treatment Landscape
https://www.delveinsight.com/sample-request/behcets-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Behcet's Disease Market Strengths
• The constant efforts by researchers to determine clear molecular pathogenesis are progressively increasing.
• Studies suggest that Behcet's syndrome shares common features with autoimmune and inflammatory disorders, thus leading to the detection of the main mediators involved in the pathomechanism of Behcet's syndrome.
Behcet's Disease Market Opportunities
• There is an attractive market for therapies with a primary goal of treatment to rapidly suppress and prevent new inflammatory attacks to avoid irreversible organ damage, especially in the early, active stages of Behcet's syndrome.
• As a consequence of escalating knowledge and awareness among providers and caregivers about Behcet's syndrome, the prevalence of the disease is increasing, which may further expedite the R&D.
Scope of the Behcet's Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Behcet's Disease Companies: Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others
• Key Behcet's Disease Therapies: SGX945, RAY121, Dusquetide, Filgotinib, Hemay005, Apremilast, and others
• Behcet's Disease Therapeutic Assessment: Behcet's Disease current marketed and Behcet's Disease emerging therapies
• Behcet's Disease Market Dynamics: Behcet's Disease market drivers and Behcet's Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Behcet's Disease Unmet Needs, KOL's views, Analyst's views, Behcet's Disease Market Access and Reimbursement
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: [email protected]
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
Delete press release Edit press release News-ID: 4379066 • Views: 6
